Efinopegdutide How It Works: Mechanism of Action Explained

Introduction

Efinopegdutide is an investigational once-weekly peptide that activates both the GLP-1 receptor and the glucagon receptor. It originated at Hanmi Pharmaceutical in South Korea (as HM12525A) and is being developed by Merck (as MK-6024) primarily for metabolic dysfunction-associated steatohepatitis (MASH) and obesity. The drug has been in phase 2 trials since 2019 with several positive readouts on liver fat and weight reduction.

This article walks through the molecular biology, the receptor activity ratio, the clinical trial evidence, and where efinopegdutide sits versus competitors like pemvidutide, semaglutide, and tirzepatide.

At TrimRx, we believe that understanding your options is the first step toward a more manageable health journey. You can take the free assessment quiz if you’re ready to see whether a personalized program is a fit for you.

What Is Efinopegdutide and What Class of Drug Is It?

Efinopegdutide is a long-acting peptide that acts as a dual agonist at the GLP-1 and glucagon receptors. It belongs to the same general class as pemvidutide, survodutide, and cotadutide (GLP-1/glucagon coagonists), distinguished from GLP-1-only drugs (semaglutide), GLP-1/GIP coagonists (tirzepatide), and triple agonists (retatrutide).

Quick Answer: Efinopegdutide is a long-acting dual GLP-1/glucagon receptor agonist designed for weekly dosing

The drug uses Hanmi Pharmaceutical’s LAPSCOVERY (Long Acting Protein/Peptide Discovery) technology. The active peptide is fused to a non-immunogenic immunoglobulin Fc fragment, which extends half-life dramatically by reducing renal clearance and enzymatic degradation. The result is a peptide with a half-life of about 7 to 10 days that supports weekly dosing.

Efinopegdutide is not FDA-approved. It’s in phase 2b for MASH with phase 3 plans in preparation. Merck acquired global development rights (outside Korea) from Hanmi in 2020.

How Does GLP-1 Receptor Activation Contribute to Efinopegdutide’s Effects?

GLP-1 receptor activation in efinopegdutide drives the same effects seen with other GLP-1-class drugs: slowed gastric emptying, appetite suppression via hypothalamic and brainstem signaling, glucose-dependent insulin secretion, and modulation of glucagon secretion from pancreatic alpha cells.

These effects are responsible for most of the weight loss and a meaningful portion of the metabolic improvement seen in trials. Patients eat less because they feel full faster and longer, and food moves through the stomach more slowly.

Pure GLP-1 agonists like semaglutide produce weight loss primarily through this appetite suppression pathway. Efinopegdutide’s GLP-1 component is potent enough to drive this on its own, with the glucagon component adding the metabolic-rate and liver-fat effects.

What Does the Glucagon Receptor Component Add?

Glucagon receptor activation increases hepatic fatty acid oxidation, raises resting energy expenditure modestly, and drives substrate switching from carbohydrate to fat. In efinopegdutide’s case, the glucagon component is what allows the drug to outperform pure GLP-1 agonists on liver fat reduction.

The trade-off is that glucagon raises hepatic glucose output. To prevent unwanted hyperglycemia, efinopegdutide is designed with a receptor activity ratio that keeps GLP-1 signaling dominant enough to drive insulin secretion and counteract glucagon’s glucose effects.

Exact ratio of GLP-1 to glucagon activity for efinopegdutide hasn’t been publicly disclosed in the same detail as for pemvidutide, but published mechanism studies suggest the molecule is GLP-1-weighted.

What Did the Phase 2a MASH Head-to-head Trial Show?

Romero-Gomez et al. published in Journal of Hepatology in 2023 the head-to-head trial comparing efinopegdutide to semaglutide in adults with MASH-related liver fat (MRI-PDFF at least 10%). The 24-week trial randomized 145 patients to efinopegdutide 10 mg weekly or semaglutide 1.0 mg weekly.

Primary results:

Relative liver fat reduction (MRI-PDFF): 72.7% for efinopegdutide, 42.3% for semaglutide.

Mean body weight loss: 8.5% for efinopegdutide, 7.1% for semaglutide.

ALT reduction: about 30 to 40% for efinopegdutide.

This was the first major head-to-head between a dual agonist and a pure GLP-1 agonist specifically for liver fat, and the results clearly favored the dual agonist. The trial established efinopegdutide as a serious contender in the MASH space.

What Is the Half-life and Why Does It Matter?

Efinopegdutide’s terminal half-life is approximately 7 to 10 days, supported by the Fc fusion protein architecture that protects the peptide from renal clearance and proteolytic breakdown. The long half-life makes once-weekly dosing straightforward and allows stable plasma concentrations throughout the dosing interval.

This is longer than semaglutide (about 7 days), comparable to or slightly longer than tirzepatide (about 5 days), and longer than pemvidutide (about 6 days).

Long half-life has practical implications. Missed doses are less likely to result in dramatic loss of effect because residual drug stays well above therapeutic threshold. Two missed doses still don’t completely clear the receptor.

What Dose Is Being Tested?

The phase 2a MASH trial used 10 mg weekly. Earlier dose-ranging studies tested doses from 1 to 10 mg. Phase 2b trials may explore additional doses; the optimal dose for the MASH indication appears to be in the 5 to 10 mg range based on liver fat dose-response.

For obesity, the optimal dose may be different. Pure obesity trials are still ongoing. Larger doses may be tested if weight loss continues to scale up.

How Does Efinopegdutide Compare to Pemvidutide?

Both are dual GLP-1/glucagon agonists with weekly dosing, both designed primarily for obesity and MASH. Key differences:

Architecture: Efinopegdutide uses an Fc fusion (larger molecule). Pemvidutide uses fatty acid acylation (smaller peptide).

Half-life: Efinopegdutide about 7 to 10 days, pemvidutide about 6 days.

Phase: Pemvidutide is also in phase 2b. Both have similar regulatory timing.

Trial design: Efinopegdutide has the only published head-to-head versus semaglutide for liver fat. Pemvidutide hasn’t run that comparison.

Receptor ratio: Pemvidutide is roughly 1:1 GLP-1 to glucagon (more glucagon-weighted than semaglutide). Efinopegdutide ratio hasn’t been publicly detailed in the same way but appears to be GLP-1-weighted.

How Does Efinopegdutide Affect Liver Fat Specifically?

MRI-PDFF (proton density fat fraction) is the gold standard imaging measure for hepatic steatosis. Efinopegdutide reduced MRI-PDFF by 72.7% at 24 weeks at the 10 mg dose in the phase 2a MASH trial. That’s one of the largest liver-fat reductions reported for any drug at that timepoint.

For comparison:

Semaglutide 1.0 mg in the same trial: 42.3% reduction.

Pemvidutide 1.2 mg in IMPACT MASH (24 weeks): 57.1% reduction.

Resmetirom 100 mg in MAESTRO-NASH (Harrison et al. 2024 NEJM, 52 weeks): about 30 to 40% reduction.

Efinopegdutide’s liver fat effect is the largest in this set, which suggests its glucagon receptor coverage is doing substantial work on hepatic biology.

Does Efinopegdutide Lower HbA1c?

The phase 2a MASH trial reported small reductions in HbA1c (about 0.3 to 0.5 percentage points) at the 10 mg dose. That’s less than semaglutide’s typical effect (about 1.0 to 1.5 percentage points) but more than pemvidutide’s near-zero effect.

The intermediate HbA1c effect suggests efinopegdutide’s glucagon component is dampening but not fully offsetting GLP-1’s glucose-lowering. The drug isn’t being developed primarily for diabetes management but may have some utility in patients with concurrent T2D and MASH.

What About Cardiovascular and Kidney Effects?

Direct cardiovascular outcomes haven’t been studied for efinopegdutide. Class effects from GLP-1 (cardiovascular benefit in SELECT, Lincoff et al. 2023 NEJM, kidney benefit in FLOW, Perkovic et al. 2024 NEJM) suggest efinopegdutide should at minimum share those.

Heart rate increases in the phase 2a MASH trial were modest (3 to 5 bpm at 10 mg). Lipid changes weren’t a major issue.

A dedicated cardiovascular outcomes trial would be needed for label expansion. Merck has the resources to run one if commercial outlook justifies the investment.

What Are the Most Common Side Effects?

GI side effects dominate the AE profile, consistent with GLP-1 class effects:

Nausea: about 40 to 50% at 10 mg.

Diarrhea: about 20 to 30%.

Constipation: about 15 to 25%.

Vomiting: about 10 to 15%.

Discontinuation for AEs in the phase 2a MASH trial was about 8 to 10%, similar to semaglutide. Most GI symptoms were mild to moderate and concentrated in the first 4 to 8 weeks of treatment.

Glucagon-specific signals (heart rate, LDL) were smaller for efinopegdutide than for pemvidutide in available data, possibly reflecting the more GLP-1-weighted ratio.

Key Takeaway: In a phase 2a MASH trial (Romero-Gomez 2023 Journal of Hepatology), efinopegdutide reduced liver fat by 72.7% versus 42.3% for semaglutide

When Will Efinopegdutide Be Available?

Earliest realistic FDA approval is 2027 to 2028, contingent on phase 3 trial success. Merck is developing the drug primarily for MASH; an obesity-only indication may or may not be pursued depending on competitive landscape.

The MASH indication may reach market first because resmetirom is the only approved MASH drug (since March 2024) and there’s room for more options. Phase 3 MASH design probably mirrors the MAESTRO-NASH structure that resmetirom used.

Compounded efinopegdutide is not legally available because the drug isn’t FDA-approved. Patients seeking GLP-1 therapy now should consider compounded semaglutide or tirzepatide through TrimRx or similar telehealth services.

How Does Efinopegdutide Fit the TrimRx Patient FLOW?

Efinopegdutide isn’t on the TrimRx formulary because it isn’t FDA-approved. The free assessment quiz routes patients to compounded semaglutide or tirzepatide based on clinical fit and goals.

When efinopegdutide is approved, TrimRx will evaluate carrying it. Patients with significant MASH may particularly benefit from efinopegdutide given the head-to-head liver fat data.

What Is the Fc Fusion Protein Technology Behind Efinopegdutide?

Hanmi’s LAPSCOVERY platform attaches the active peptide to a non-immunogenic immunoglobulin Fc fragment. The Fc fragment is the part of an antibody that binds to neonatal Fc receptors (FcRn), which recycle the molecule back into circulation rather than letting it get cleared. The result is a peptide drug that behaves pharmacokinetically more like a monoclonal antibody than a typical peptide.

This is a different approach from semaglutide and pemvidutide, which use fatty acid acylation to bind albumin for the same goal of extended half-life. Tirzepatide also uses fatty acid acylation. Efinopegdutide is unusual in the GLP-1-class space for using Fc fusion.

The clinical implications include slower elimination, more stable plasma levels week to week, and possibly less variability in dose-response between patients. The molecule is larger than typical GLP-1 peptides because of the Fc fragment, which doesn’t affect potency but does change manufacturing and formulation considerations.

How Does Efinopegdutide Affect Appetite Specifically?

GLP-1 receptor activation in the hypothalamic arcuate nucleus reduces hunger signals. Patients on efinopegdutide report similar appetite changes to those described with semaglutide: less interest in food, smaller portions feeling satisfying, longer intervals between hunger cues, and reduced cravings for high-fat or high-sugar foods.

The brainstem area postrema and nucleus tractus solitarius also receive GLP-1 signals. Activation here drives both satiety and nausea, which is why nausea is the most common side effect early in treatment. Adaptation occurs over weeks for the nausea pathway but persists for the satiety pathway.

Some patients describe a “food noise” reduction on GLP-1 drugs, a quieting of intrusive food thoughts. Whether efinopegdutide produces this effect more or less than semaglutide isn’t documented in published trials but appetite scoring metrics in phase 2 looked similar.

What Does the Glucagon Component Do at the Molecular Level?

Glucagon receptor activation triggers a cAMP signaling cascade in liver cells. Downstream effects include increased fatty acid oxidation (the liver burns through stored triglycerides), increased gluconeogenesis (the liver makes new glucose from amino acids and other substrates), and increased ketogenesis (when carbohydrate is low).

In the context of efinopegdutide treatment, the dominant beneficial effect is fatty acid oxidation, which reduces hepatic triglyceride content. That’s why MRI-PDFF liver fat drops substantially on efinopegdutide.

The unwanted glucagon effects (raising blood glucose, modest LDL increases) are kept in check by the GLP-1 component’s insulin secretion and other counter-regulatory mechanisms. The balance is what makes the dual agonist approach work.

How Does Efinopegdutide Affect Energy Expenditure?

Glucagon receptor activation increases resting energy expenditure by an estimated 5 to 10% based on animal and early human studies. The mechanism involves brown adipose tissue activation, increased liver thermogenesis, and altered substrate utilization that wastes more energy per gram of food.

For efinopegdutide specifically, dedicated energy expenditure measurements haven’t been widely published. The 5 to 10% range is the general expectation for any glucagon-receptor-active drug.

In practical terms, a 5% increase in resting metabolic rate for a typical adult adds about 75 to 100 calories per day burned at rest. Combined with appetite suppression and reduced food intake, this contributes to the favorable weight loss curves seen in trials.

How Does Efinopegdutide Differ Structurally From Semaglutide?

Semaglutide is a 31-amino-acid peptide with a single fatty acid modification. It binds GLP-1 receptors selectively.

Efinopegdutide is a peptide-Fc fusion protein. The active peptide portion shares sequence homology with both GLP-1 and glucagon, allowing it to bind both receptors. The Fc fragment extends half-life.

Tirzepatide is a 39-amino-acid peptide with a fatty acid modification, designed to bind GLP-1 and GIP receptors but not glucagon.

These structural differences translate into the different receptor coverage and efficacy profiles seen in trials.

What’s the Relationship Between Efinopegdutide and GLP-2?

GLP-1 and GLP-2 are both products of proglucagon gene processing. GLP-2 has effects on gut growth and integrity. Efinopegdutide doesn’t activate GLP-2 receptors specifically; the drug is designed for GLP-1 and glucagon receptors only.

GLP-2 analogs (like teduglutide) are used for short bowel syndrome, a separate clinical application.

Does Efinopegdutide Affect Bone Density?

Significant weight loss can affect bone density. The phase 2 efinopegdutide trials didn’t include DEXA bone density measurements. Class-wide GLP-1 data doesn’t show major bone density signals.

Patients at risk for osteoporosis (postmenopausal women, older adults, those with low baseline bone density) should ensure adequate calcium, vitamin D, and weight-bearing exercise during GLP-1 therapy.

What About Effects on the Gut Microbiome?

GLP-1 drugs may affect gut microbiome composition through changes in eating patterns, gut transit time, and direct effects on intestinal cells. Specific data for efinopegdutide isn’t published.

Microbiome changes could theoretically affect long-term outcomes (immune function, mood, weight regulation) but the clinical significance isn’t established.

Bottom line: Currently in phase 2b for MASH; phase 3 program in planning

FAQ

Is Efinopegdutide Stronger Than Semaglutide for Weight Loss?

In the phase 2a MASH head-to-head, 8.5% vs 7.1% at 24 weeks. Modestly better, with much larger liver fat effects.

Will Efinopegdutide Be the Next Big GLP-1 Drug?

Likely a significant entry for MASH. The obesity-only positioning is less clear; competition from tirzepatide, pemvidutide, retatrutide, and CagriSema is fierce.

What’s the Difference Between Efinopegdutide and Pemvidutide?

Same drug class, different molecules. Different half-lives, different exact receptor ratios, different sponsor strategies.

Can I Get Efinopegdutide Now?

Only through clinical trials. Search clinicaltrials.gov for active studies.

Is Efinopegdutide Approved for MASH?

Not yet. Phase 2b is ongoing, phase 3 is in planning. Earliest approval is 2027 to 2028.

Does Efinopegdutide Have CV Outcomes Data?

No dedicated cardiovascular outcomes trial has been completed. Class effects suggest CV benefit, but direct data isn’t available.

What’s Merck’s Strategy with Efinopegdutide?

Primary focus is MASH, where the head-to-head versus semaglutide data is strong. Obesity is secondary but possible.

Disclaimer: This content is for informational purposes only and does not constitute medical advice. It is not intended to diagnose, treat, cure, or prevent any disease or condition. Individual results may vary. Always consult a qualified healthcare professional before starting any weight loss program or medication.